Cancer risk in association with Parkinson disease: A population-based study |
| |
| Institution: | 1. Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK;2. UK Dementia Research Institute (UK DRI) at UCL, London, UK;3. UK Dementia Research Institute (UK DRI) at Cardiff, MRC Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, Cardiff, UK;4. Laboratory of Neurogenetics, National Institutes on Aging, NIH, Bethesda, MD, USA;5. German Center for Neurodegenerative Diseases (DZNE)-Tubingen, Germany;6. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA;7. Genetics and Pharmacogenomics, Merck Research Laboratories, Boston, MA, USA;8. Neuroscience Research Australia, Sydney, Australia and School of Medical Sciences, Faculty of Medicine, University of New South Wales, Sydney, Australia;9. Nuffield Department of Clinical Neurosciences, Oxford Parkinsons Disease Centre, University of Oxford, Oxford, UK;10. Division of Biomedical Statistics and Informatics, Mayo Clinic, Jacksonville, FL, USA;11. Neurodegenerative Diseases Research Unit, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA;12. Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, USA;13. Department of Pathology (Neuropathology), Johns Hopkins University School of Medicine, Baltimore, MD, USA;14. Memory Unit, Department of Neurology, IIB Sant Pau, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain;15. Taub Institute for Alzheimer Disease and the Aging Brain, Department of Pathology and Cell Biology, Columbia University, New York, NY, USA;p. Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands;q. Tanz Centre for Research in Neurodegenerative Diseases and department of Medicine, University of Toronto, Ontario, Canada;r. Department of Clinical Neurosciences, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK;s. Clinical Memory Research Unit, Institution of Clinical Sciences Malmo, Lund University, Sweden;t. UK Dementia Research Institute at UCL, London UK, Department of Neurodegenerative Diseases, UCL Institute of Neurology, London, UK, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Molndal, Sweden;u. Human Genetics, School of Life Sciences, Queens Medical Centre, University of Nottingham, Nottingham, UK;v. Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, Kings College London, London, UK;w. Queen Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK;x. Queen Square Brain Bank, Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK, Movement Disorders Unit, Neurology Service, Clinical Neuroscience Institute (ICN), Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Catalonia, Spain;y. Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania, 3600 Spruce Street, Philadelphia, USA;z. Banner Sun Health Research Institute, 10515 W Santa Fe Drive, Sun City, AZ 85351, USA;11. Inserm U1127, CNRS UMR7225, Sorbonne Universites, UPMC Univ Paris 06, UMR and S1127, Institut du Cerveau et de la Moelle epiniere, Paris, France;12. Department of Neurosciences, University of California, San Diego, La Jolla, CA, United States, Veterans Affairs San Diego Healthcare System, La Jolla, CA, United States;13. Department of Neurosciences, University of California, San Diego, La Jolla, CA, United States, Department of Pathology, University of California, San Diego, La Jolla, CA, United States;14. Neurology Department, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal; Faculty of Medicine and Centre for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal;15. Memory Unit, Department of Neurology,University Hospital Mutua de Terrassa, University of Barcelona, Fundacion de Docencia I Recerca Mutua de Terrassa, Terrassa, Barcelona, Spain. Centro de Investigacion Biomedica en Red Enfermedades Neurdegenerativas (CIBERNED), Madrid, Spain;16. Molecular Neurology, Research Programs Unit, University of Helsinki, Department of Neurology, Helsinki University Hospital, Helsinki, Finland;17. Department of Pathology, University of Helsinki, Helsinki University Hospital, Helsinki, Finland;18. Department of Neuropathology and Neurosurgery, Helsinki University Hospital, University of Helsinki, Helsinki, Finland;19. Neurology Department, Mayo Clinic, Rochester, MN, USA;110. Department of Psychiatry and Department of Psychology, Mayo Clinic, Jacksonville, FL, USA;111. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA;112. Knight Alzheimers Disease Research Center, Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA;113. Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, Manchester, UK;114. Brain and Mind Centre, Sydney Medical School, The University of Sydney, Sydney, Australia;115. Genetics and Pharmacogenomics, Merck Research Laboratories, West Point, PA, USA;1p. Centro de Investigacion Biomedica en Red en Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain;1. Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China;2. Department of Infectious Diseases, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fuzhou, Fujian, China;3. Fujian HIV/AIDS Diagnosis and Treatment Center, Fuzhou, Fujian, China;4. Department of Neurology, No. 476 Hospital of Fuzhou General Hospital, Nanjing Military Region, Chinese People''s Liberation Army, Fuzhou, Fujian, China;1. Center for Neurodegenerative Science, Van Andel Institute, Grand Rapids, MI, USA;2. Section of Infections of the Nervous System, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA;3. Division of Medicine, Neurology and Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA |
| |
| Abstract: | PurposeData from large population-based studies on the association between Parkinson disease (PD) and the risk of developing cancer are scarce. We compared the risk of developing incident cancer between patients with or without PD.MethodsWe conducted a population-based follow-up study and a nested case-control analysis using data from the UK-based General Practice Research Database. We included PD patients aged ≥40 years with a first PD diagnosis between 1994 and 2005, and a matched comparison group free of PD. We assessed cancer incidence rates and relative risk estimates (odds ratios ORs] with 95% confidence intervals CI]).ResultsThe risk of developing cancer overall was lower in PD patients as compared to patients without PD (crude incidence rate ratio 0.77, 95% CI 0.64–0.92). In the nested case-control analysis (adj. OR for all cancers 0.72, 95% CI 0.59–0.87) the risk reduction was strongest for smoking-related cancers (adj. OR 0.47, 95% CI 0.31–0.72). The adjusted OR for hematological malignancies was 0.32 (95% CI 0.14–0.74). Due to small numbers, ORs for other cancer entities did not reach statistical significance.ConclusionsWith the exception of melanoma, PD patients were less likely to develop cancer than individuals without PD in this large observational study. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
